RxDoctor Payments DataLook up a doctor →

Kevin Kahn, MD

Neurology · Durham, NCNPI 1013088350

Payments from drug & device makers

$587,474in general payments, 2019–2025

Across 1,408 payments — averaging $417.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$221K
  • Amgen$110K
  • Lilly USA, LLC$67K
  • Biohaven Pharmaceuticals, Inc.$59K
  • Teva Pharmaceuticals USA, Inc.$54K
  • Axsome Therapeutics, Inc.$29K
  • plus $47K from 34 others

What the payments were for

  • Consulting fees$28,8435%
  • Speaking & faculty fees$490,91084%
  • Grants$850%
  • Travel & lodging$40,0527%
  • Food & beverage$27,5635%
  • Education$200%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$587,474 in reported general payments places this provider in the 90th percentile of 566 neurology providers in North Carolina.

See all neurology providers in North Carolina

Medicare billing

Part B allowed, 2024
$188,955
Medicare patients
141
Services billed
21,790

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate109$185,217
Aimovig AutoinjectorErenumab-Aooe203$182,758
UbrelvyUbrogepant108$162,314
Emgality PenGalcanezumab-Gnlm170$139,472
Emgality SyringeGalcanezumab-Gnlm74$119,573
BotoxOnabotulinumtoxina75$97,100
QuliptaAtogepant61$81,102
Ajovy AutoinjectorFremanezumab-Vfrm42$46,936
Topiramate ErTopiramate26$33,307
BelsomraSuvorexant41$21,854
NuedextaDextromethorphan Hbr/Quinidine12$18,529
QuviviqDaridorexant Hcl25$11,905
CambiaDiclofenac Potassium12$10,598
OxycontinOxycodone Hcl12$9,510
Sumatriptan Succinate140$9,281

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Botox, Qulipta$221,301$340,515244 claims
PfizerNurtec Odt$12,606$185,217109 claims
MerckBelsomra$94$21,85441 claims
Avanir Pharmaceuticals, Inc.Nuedexta$261$18,52912 claims
Idorsia Pharmaceuticals US IncQuviviq$209$11,90525 claims
Assertio Therapeutics, Inc.Cambia$181$10,59812 claims
Arbor Pharmaceuticals, Inc.Horizant$309$7,05512 claims
Upsher-smith Laboratories LLCTopiramate$846$2,150101 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 566 neurology providers in North Carolina.

Other neurology in Durham

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →